Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
16
QNCX Quote, Financials, Valuation and Earnings
Last price:
$0.10
Seasonality move
:
-1.12%
Day range:
$0.10 - $0.11
52-week range:
$0.10 - $4.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
6.61x
Volume:
26.9M
Avg. volume:
113.7M
1-year change:
-90.96%
Market cap:
$7M
Revenue:
--
EPS (TTM):
-$1.22
Analysts' Opinion
-
Consensus RatingQuince Therapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 3 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $5.00, Quince Therapeutics, Inc. has an estimated downside of -100% from its current price of $0.13.
-
Price Target UpsideAccording to analysts, the highest upside price target is $10.00 representing -100% upside increase from its current price of $0.13.
Fair Value
-
According to the consensus of 4 analysts, Quince Therapeutics, Inc. has -100% downside to fair value with a price target of $5.00 per share.
QNCX vs. S&P 500
-
Over the past 5 trading days, Quince Therapeutics, Inc. has underperformed the S&P 500 by -15.88% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Quince Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Quince Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Quince Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Quince Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Quince Therapeutics, Inc. reported earnings per share of -$0.25.
Enterprise value:
-1.3M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$119K
Return On Assets:
-48.55%
Net Income Margin (TTM):
--
Return On Equity:
-267.62%
Return On Invested Capital:
-151.58%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$60K | -$474K | -$119K | -$86K | -$36K | |
| Operating Income | -$25.1M | -$31.9M | -$44.3M | -$8.5M | -$11.4M | |
| EBITDA | -$25M | -$31.4M | -$44.2M | -$8.5M | -$11.3M | |
| Diluted EPS | -$0.78 | -$1.25 | -$1.22 | -$0.13 | -$0.25 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $119.4M | $98.3M | $85.2M | $51.7M | $29.2M | |
| Total Assets | $147.4M | $109.8M | $85.4M | $126.5M | $109.9M | |
| Current Liabilities | $14.2M | $4.9M | $2.3M | $5.4M | $26M | |
| Total Liabilities | $14.8M | $5.2M | $2.3M | $81.6M | $108.8M | |
| Total Equity | $132.7M | $104.5M | $83.1M | $44.9M | $1.1M | |
| Total Debt | $610K | $128K | -- | $15.3M | $359K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$18M | -$30.4M | -$38.5M | -$7.3M | -$9.9M | |
| Cash From Investing | $7.5M | $16.4M | $26M | $7.1M | -$1.8M | |
| Cash From Financing | $68K | -$4.7M | $15.9M | -$5M | $1.4M | |
| Free Cash Flow | -$18.3M | -$30.6M | -$39M | -$7.3M | -$10M | |
QNCX
Sector
Market Cap
$7M
$25.5M
Price % of 52-Week High
2.76%
50%
Dividend Yield
0%
0%
Shareholder Yield
-18.69%
-1.62%
1-Year Price Total Return
-90.96%
-18.12%
Beta (5-Year)
1.282
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.15
200-day SMA
Sell
Level
$1.83
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$0.20
Relative Strength Index (RSI14)
Sell
Level
27.19
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-97.3564
50-day SMA
Sell
Level
$1.96
MACD (12, 26)
Buy
Level
0.04
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.2602)
Sell
CA Score
(Annual)
Level (-2.0992)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (4.3991)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. Its product includes EryDex, developed using their proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which is a novel device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, QNCX has received 1 Buy ratings 3 Hold ratings, and 0 Sell ratings. The QNCX average analyst price target in the past 3 months is $5.00.
-
Where Will Quince Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Quince Therapeutics, Inc. share price will drop to $5.00 per share over the next 12 months.
-
What Do Analysts Say About Quince Therapeutics, Inc.?
Analysts are divided on their view about Quince Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Quince Therapeutics, Inc. is a Sell and believe this share price will rise from its current level to $0.00.
-
What Is Quince Therapeutics, Inc.'s Price Target?
The price target for Quince Therapeutics, Inc. over the next 1-year time period is forecast to be $5.00 according to 4 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is QNCX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Quince Therapeutics, Inc. is a Hold. 3 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of QNCX?
You can purchase shares of Quince Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Quince Therapeutics, Inc. shares.
-
What Is The Quince Therapeutics, Inc. Share Price Today?
Quince Therapeutics, Inc. was last trading at $0.10 per share. This represents the most recent stock quote for Quince Therapeutics, Inc.. Yesterday, Quince Therapeutics, Inc. closed at $0.13 per share.
-
How To Buy Quince Therapeutics, Inc. Stock Online?
In order to purchase Quince Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get QNCX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
QNCX
Sector
P/E ratio
--
23.08x
PEG ratio
--
-0.01x
P/B ratio
6.61x
1.81x
Price / LTM sales
--
1.54x
Growth Metrics
QNCX
Sector
Revenue growth
--
3.44%
Earnings growth
-95.91%
11.11%
Revenue (5-year growth)
--
6.46%
Earnings forecast
-$0.23
-$0.19
Profitability
QNCX
Sector
Profitability FY 2024
-$186K
$2.4M
Return on invested capital
-151.58%
-33.43%
Return on assets
-48.55%
-29.79%
Return on equity
-267.62%
-39.31%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
23
Estimated Next Earnings Date
Feb
11
Balance Sheet
QNCX
Sector
Total cash
$26.3M
$24.1M
Short term investments
$34.6M
$23.8M
Total assets
$126.2M
$70.2M
Long term debt
$359K
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is up 21.71% over the past day.
Buy
90
BNAI alert for Mar 2
Brand Engagement Network, Inc. [BNAI] is up 2.44% over the past day.
Sell
36
WLDN alert for Mar 2
Willdan Group, Inc. [WLDN] is down 1.93% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
